Views & Analysis UK funding of cancer drugs: right, wrong, or just plain conf... How do the countries of the UK fund cancer drugs today, and do they have the right approaches?
R&D Precision, speed, impact: Evolving mass spectrometry for med... MOBILion's Melissa Sherman explores the evolving role of mass spectrometry in drug discovery, complex molecule analysis, and medical research.
Market Access The value of a partner, globally and locally A new podcast looks at recent trends related to drug approvals, as well as challenges and opportunities both small and large pharma companies face